PolarCool signs an agreement with Portugal’s National Rugby Team
The med-tech company PolarCool AB (publ) continues its successful expansion in international rugby by signing an agreement with Portugal’s National Rugby Team. The partnership provides the Portuguese national team access to the PolarCap® System during the 2023 Rugby World Cup in France and throughout the following rugby season.
PolarCool develops and markets the product PolarCap®, which alleviates the effects of concussion. The primary users of PolarCap® include sports clubs, organizations, and facilities in contact sports such as ice hockey, rugby, football, and handball, but also other sports with an increased risk of concussion.
PolarCool has had several successes in international rugby. The agreement with Portugal Rugby will be the third in a series of nations to sign agreements enabling them to provide treatment with PolarCap® System. The company has recently partnered with Rugby Australia and Georgia Rugby, who together with Portugal Rugby will provide the PolarCap® System during the 2023 Rugby World Cup.
Portugal Rugby Chief Medical Officer, Dr António Cruz Ferreira comments;
-As the medical doctor for Portugal Rugby, I am looking forward to getting first-hand experience of the PolarCap® System. We have evaluated the clinical evidence for the treatment and welcome new innovations aimed at improving the acute management of concussions.
PolarCool CEO Erik Andersson comments;
-We have actively worked on the international rugby market to establish the PolarCap® System. It is very gratifying that we now see the results of the extensive efforts we carried out during the year. We now look forward to continuing this successful momentum within professional rugby.
The agreements align with PolarCool's overall strategy to introduce the treatment to the professional rugby market. The agreement is strategically important, even if the financial impact of individual agreements is limited.
For more information
Erik Andersson – CEO PolarCool AB (publ)
+46 - 738 60 57 00
E-mail: [email protected]
About PolarCool AB (publ)
PolarCool AB (publ) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap® System. PolarCool AB (publ) is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.
PolarCool Board members and Management subscribe for all their unit rights in the company's ongoing rights issue
-The future for PolarCool is exciting and we welcome everyone, also new shareholders without unit rights, to participate in the rights issue. The registration form, memorandum and teaser are available on Nordic Issuing's website www.nordic-issuing.se, Spotlight Stock Market's website https://www.spo...
Styrelsemedlemmar och ledning i PolarCool tecknar samtliga sina uniträtter i bolagets pågående företrädesemission
-Framtiden för PolarCool är väldigt spännande och vi välkomnar alla, även nya aktieägare utan uniträtter att delta i emissionen. Anmälningssedel, prospekt och teaser finns tillgängligt på Nordic Issuings hemsida www.nordic-issuing.se, Spotlight Stock Markets hemsida www.spotlightstockmarket.com samt...
Integrum attends international expert workshop on osseointegration and bionic limb reconstruction
Mölndal, Sweden, September 27, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company is attending an international meeting and workshop event gathering experts in the field of osseointegration and bionic limb reconstruction, at the prestigious Rizzoli Or...
Capital increase in Monsenso A/S as a result of warrants exercising of employees
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares entitle to dividends and other rights in the company from the time of registration of the capital increase. The new shares will be admitted to listing on Nasdaq First Nort...